. 2012 Oct 27;13(4):1502–1510. doi: 10.1208/s12249-012-9871-7

Table IV.

Stability Study of Optimized Niosomal (F3c) and Ethosomal (E5) Dispersions

S. No.	Formulation	Time (in months)	Vesicular size^a (nm)		% drug retained^a
S. No.	Formulation	Time (in months)	2–8°C	30 ± 2°C	2–8°C	30 ± 2°C
1	F3c dispersion	0	105.76 ± 1.24	105.76 ± 1.24	100	100
2		1	109.24 ± 2.16	138.18 ± 3.75	96.23 ± 0.458	54.43 ± 0.538
3		2	115.31 ± 1.87	186.51 ± 2.66	91.18 ± 0.759	39.32 ± 0.346
4	E5 dispersion	0	113.3 ± 5.43	113.3 ± 5.43	100	100
5		1	143.6 ± 1.09	198.72 ± 2.13	85.79 ± 2.983	43.12 ± 5.789
6		2	178.2 ± 6.83	301.68 ± 7.69	69.52 ± 4.191	23.73 ± 2.443

^aValues represented as mean ± SD (n = 3)